Investigation Of IL-6 And Its Related Tumor-associated Biomarkers

Objective Recent researches enhance our pavements in recognizing the close link between inflammation and tumor.The inflammatory cytokines can act as a crucial joint between these two diseases via their regulation on various tumor-associated signaling pathways,thus promoting carcinogenesis of inflammation and metastasis of tumor,casting inflammatory cytokines in the role of novel tumor biomarkers.Interleukin-6(IL-6)overexpression usually accompanies with inflammation and various cancers,and elevated level of IL-6 in tumor microenvironment highlights its essential role in transition between them.Our study aims to investigate IL-6 along with other clinical parameters in inflammatory and tumor patients.We are also able to find its downstream oncogenes,Jab1 and HOTAIR and make further query for their tumor regulatory mechanisms.Methods We retrospect 1072 patients at Zhongnan Hospital of Wuhan University from Jan 2018 to Dec 2018.Among these patients,400 cases were diagnosed with inflammation,and the other 672 tumor cases were composed of 338 patients with hematological malignancies and 334 patients with solid tumors.Comparisons were made among these groups and statistical differentiated immunological indexes were IL-6 and neutrophils/lymphocytes ratio(NLR),then the significant role of IL-6 in tumor regulatory networks supported our results.By querying the Oncomine database,we investigated Jab1 and HOTAIR,the downstream oncogenes of IL-6,and confirmed their overexpression in a good number of cancer types.Conclusion Most of the present indexes have capacity of monitoring the tumorigenesis of inflammatory patients clinically,and the predictive value of immunological parameters were superior to the other serological indexes.Remarkable indexes including IL-6,systemic inflammatory response index(SIRI),NLR,systemic immune-inflammatory response index(SII)and platelet/lymphocytes ratio(PLR)were of great clinical significance in inflammation and its tumorigenesis.Of note,these indexes didn’t require any additional expenditure and were of reasonable accuracy and specificity in addition to timely diagnosis.Novel indicator composed of IL-6 and NLR may improve our current clinical diagnosis of cancer and provide more ideal treatment and prognosis.Downstream oncogenes of IL-6,Jab1 and HOTAIR,can also be promising target for tumor therapy and broaden our insight into tumor-related biomarkers.